Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Roth

Showing results (21-30 of 53) with videos related to

Pageof 6
Sort By:
Annals of the Rheumatic Diseases|February 17, 2012
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of responseRonald F van Vollenhoven, Michelle A Petri, Ricard Cervera, et al.
RMD Open|July 3, 2021
Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South KoreaYoshiya Tanaka, Sang-Cheol Bae, Damon Bass, et al.
ACR Open Rheumatology|June 24, 2022
EMBRACE: One Small Story in Lupus-One Giant Challenge in Clinical TrialsSaira Z Sheikh, Tessa R Englund, Susan W Burriss, et al.
Clinical Journal of the American Society of Nephrology : CJASN|October 27, 2022
Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN StudyRichard Furie, Brad H Rovin, Frédéric Houssiau, et al.
Environmental Science & Technology|March 9, 2011
Lagrangian mass-flow investigations of inorganic contaminants in wastewater-impacted streamsLarry B Barber, Ronald C Antweiler, Jennifer L Flynn, et al.
Lupus|July 9, 2021
10 Years of belimumab experience: What have we learnt?Roger A Levy, Tania Gonzalez-Rivera, Munther Khamashta, et al.
Kidney International|April 29, 2026
Insights from the BLISS-LN Phase 3 study of biomarker associations with kidney response to belimumab in lupus nephritisBrad H Rovin, Richard Furie, Ana Malvar, et al.
Modern Rheumatology|October 8, 2022
Efficacy of belimumab in patients with systemic lupus erythematosus from North East Asia: Results of exploratory subgroup analysesJie Zheng, Jieruo Gu, Yin Su, et al.
Kidney International|September 24, 2021
A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritisBrad H Rovin, Richard Furie, Y K Onno Teng, et al.
Arthritis Research & Therapy|February 17, 2022
The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week studySang-Cheol Bae, Damon L Bass, Myron Chu, et al.
Pageof 6

Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Annals of the Rheumatic Diseases|February 17, 2012
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of responseRonald F van Vollenhoven, Michelle A Petri, Ricard Cervera, et al.
RMD Open|July 3, 2021
Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South KoreaYoshiya Tanaka, Sang-Cheol Bae, Damon Bass, et al.
ACR Open Rheumatology|June 24, 2022
EMBRACE: One Small Story in Lupus-One Giant Challenge in Clinical TrialsSaira Z Sheikh, Tessa R Englund, Susan W Burriss, et al.
Clinical Journal of the American Society of Nephrology : CJASN|October 27, 2022
Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN StudyRichard Furie, Brad H Rovin, Frédéric Houssiau, et al.
Environmental Science & Technology|March 9, 2011
Lagrangian mass-flow investigations of inorganic contaminants in wastewater-impacted streamsLarry B Barber, Ronald C Antweiler, Jennifer L Flynn, et al.
Lupus|July 9, 2021
10 Years of belimumab experience: What have we learnt?Roger A Levy, Tania Gonzalez-Rivera, Munther Khamashta, et al.
Kidney International|April 29, 2026
Insights from the BLISS-LN Phase 3 study of biomarker associations with kidney response to belimumab in lupus nephritisBrad H Rovin, Richard Furie, Ana Malvar, et al.
Modern Rheumatology|October 8, 2022
Efficacy of belimumab in patients with systemic lupus erythematosus from North East Asia: Results of exploratory subgroup analysesJie Zheng, Jieruo Gu, Yin Su, et al.
Kidney International|September 24, 2021
A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritisBrad H Rovin, Richard Furie, Y K Onno Teng, et al.
Arthritis Research & Therapy|February 17, 2022
The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week studySang-Cheol Bae, Damon L Bass, Myron Chu, et al.
Pageof 6